
    
      This study was a Phase 1 and pharmacologic dose-escalation trial of MM-121 plus cetuximab
      plus irinotecan. The study assessed the safety, tolerability, and pharmacokinetics of MM-121,
      cetuximab and irinotecan.
    
  